HMGA1 Overexpression is Associated With the Malignant Status and Progression of Breast Cancer

Qi, Cuiling; Cao, Jinghua; Li, Mengshi; Liang, Chenghua; He, Yang; Li, Yuanyuan; Li, Jialin; Zheng, Xiaoming; Wang, Lijing; Wei, Bo

doi:10.1002/ar.23777

Cited by 13 publications

(11 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our findings showed slightly higher HMGA1 expression in initial biopsies taken from non-responders, as well as an inverse expression pattern in post-induction biopsies (Figure 4B), but these results and, similarly, the results of the survival analysis (Figures 5C,D) were not statistically significant. Nevertheless, such trends in expression—although non-significant—are in accordance with recent knowledge on the importance of HMGA1 as a “master regulator” in tumorigenesis and its association with tumor aggressiveness (32, 34, 38).…”

Section: Discussionsupporting

confidence: 86%

“…Treatment with retinoids can change the expression of HMGA1, and these changes are closely related to MYCN status (30, 31). Although there are no data on the possible relationship between HMGA1 expression and clinical outcome in patients suffering from NBL, published studies on other cancer types suggest that HMGA1 overexpression is associated with aggressive tumor behavior and poor prognosis: such findings were reported for breast carcinoma (32–34), pancreatic adenocarcinoma (35), esophageal squamous cell carcinoma (36), non-small cell lung cancer (37), and uveal melanomas (38). In contrast, such results were not confirmed by other research groups for gastric cancer (39) and non-small cell lung cancer (40).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Comparative Analysis of Putative Prognostic and Predictive Markers in Neuroblastomas: High Expression of PBX1 Is Associated With a Poor Response to Induction Therapy

et al. 2019

View full text Add to dashboard Cite

The survival rate for patients with high-risk neuroblastomas remains poor despite new improvements in available therapeutic modalities. A detailed understanding of the mechanisms underlying clinical responses to multimodal treatment is one of the important aspects that may provide precision in the prediction of a patient's clinical outcome. Our study was designed as a detailed comparative analysis of five selected proteins (DDX39A, HMGA1, HOXC9, NF1, and PBX1) in one cohort of patients using the same methodical approaches. These proteins were already reported separately as related to the resistance or sensitivity to retinoids and as useful prognostic markers of survival probability. In the cohort of 19 patients suffering from high-risk neuroblastomas, we analyzed initial immunohistochemistry samples obtained by diagnostic biopsy and post-induction samples taken after the end of induction therapy. The expression of DDX39A, HMGA1, HOXC9, and NF1 showed varied patterns with almost no differences between responders and non-responders. Nevertheless, we found very interesting results for PBX1: non-responders had significantly higher expression levels of this protein in the initial tumor samples when compared with responders; this expression pattern changed inversely in the post-induction samples, and this change was also statistically significant. Moreover, our results from survival analyses reveal the prognostic value of PBX1, NF1, and HOXC9 expression in neuroblastoma tissue. In addition to the prognostic importance of PBX1, NF1, and HOXC9 proteins, our results demonstrated that PBX1 could be used for the prediction of the clinical response to induction chemotherapy in patients suffering from high-risk neuroblastoma.

show abstract

Section: Discussionsupporting

confidence: 86%

Section: Discussionmentioning

confidence: 99%

Comparative Analysis of Putative Prognostic and Predictive Markers in Neuroblastomas: High Expression of PBX1 Is Associated With a Poor Response to Induction Therapy

et al. 2019

View full text Add to dashboard Cite

show abstract

“… 41–43 Amounting studies proved that the suppression of oncogenic HMGA1 significantly inhibited some cancer cell proliferation and migration, providing a novel clue to probe into anti-cancer approaches. 21 , 29 , 32 , 44 , 45 Furthermore, HMGA1 is up-regulated in a significant proportion of HCC, and its overexpression is associated with a poor prognosis. A research in vitro models ulteriorly elucidated that HMGA1 overexpression may act a pivotal role in cell viability and migration and promote anchorage-independent growth to induce transformation in liver cancer cell lines.…”

Section: Discussionmentioning

confidence: 99%

High-Mobility Group AT-Hook 1 Served as a Prognosis Biomarker and Associated with Immune Infiltrate in Hepatocellular Carcinoma

Wei¹,

Yang²,

Wei³

et al. 2022

IJGM

View full text Add to dashboard Cite

Background The protein high-mobility group AT-hook 1 (HMGA1) has been demonstrated that modulated cellular proliferation, invasion, and apoptosis with a poor prognosis in miscellaneous carcinomas. However, the mechanism of circumstantial carcinogenesis and association with the immune microenvironment of HMGA1 in hepatocellular carcinoma (HCC) had not been extensively explored. Methods The gene expression, clinicopathological correlation, and prognosis analysis were performed in the data obtained from TCGA. The results were further validated by ICGC and GEO database and external validation cohort from Guangxi. The HMGA1 protein expression was further examined in the HPA database. Biological function analyses were conducted by GSEA, STRING database, and Coexpedia online tool. Using TIMER and CIBERSORT method, the relationship between immune infiltrate and HMGA1 was investigated. Results In HCC, HMGA1 had much higher transcriptional and proteomic expression than in corresponding paraneoplastic tissue. Patients with high HMGA1 expression had a poor prognosis and unpromising clinicopathological features. High HMGA1 expression was closely related to the cell cycle, tumorigenesis, substance metabolism, and immune processes by regulating complex signaling pathways. Notably, HMGA1 may be associated with TP53 mutational carcinogenesis. Moreover, increased HMGA1 expression may lead to an increase in immune infiltration and a decrease in tumor purity in HCC. CIBERSORT analysis elucidated that the amount of B cell naive, B cell memory, T cells gamma delta, macrophages M2, and mast cell resting decreased when HMGA1 expression was high, whereas T cells follicular helper, macrophages M0, and Dendritic cells resting increased. Conclusion In conclusions, HMGA1 is a potent prognostic biomarker and a sign of immune infiltration in HCC, which may be a potential immunotherapy target for HCC.

show abstract

“…High expression of HMGA1 has been reported to play an important role in embryonic development [ 22 , 23 ]. Recent studies have revealed that HMGA1 is associated with various types of cancers including breast [ 24 , 25 ], lung [ 26 , 27 ], and colorectal [ 28 , 29 ] cancer types. Although several studies have shown that HMGA1 plays an important role in the development of HCC [ 30 , 31 ], only one study has reported that the recurrence rate of HCC correlated with high HMGA1 mRNA expression and that it could be used as a prognostic marker for HCC [ 32 ].…”

Section: Discussionmentioning

confidence: 99%

Novel Gene Signatures as Prognostic Biomarkers for Predicting the Recurrence of Hepatocellular Carcinoma

Son

Ahn

You

et al. 2022

Cancers

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) has a high rate of cancer recurrence (up to 70%) in patients who undergo surgical resection. We investigated prognostic gene signatures for predicting HCC recurrence using in silico gene expression analysis. Recurrence-associated gene candidates were chosen by a comparative analysis of gene expression profiles from two independent whole-transcriptome datasets in patients with HCC who underwent surgical resection. Five promising candidate genes, CETN2, HMGA1, MPZL1, RACGAP1, and SNRPB were identified, and the expression of these genes was evaluated using quantitative reverse transcription PCR in the validation set (n = 57). The genes CETN2, HMGA1, RACGAP1, and SNRPB, but not MPZL1, were upregulated in patients with recurrent HCC. In addition, the combination of HMGA1 and MPZL1 demonstrated the best area under the curve (0.807, 95% confidence interval [CI] = 0.681–0.899) for predicting HCC recurrence. In terms of clinicopathological correlation, CETN2, MPZL1, RACGAP1, and SNRPB were upregulated in patients with microvascular invasion, and the expression of MPZL1 and SNRPB was increased in proportion to the Edmonson tumor differentiation grade. Additionally, overexpression of CETN2, HMGA1, and RACGAP1 correlated with poor overall survival (OS) and disease-free survival (DFS) in the validation set. Finally, Cox regression analysis showed that the expression of serum alpha-fetoprotein and RACGAP1 significantly affected OS, whereas platelet count, microvascular invasion, and HMGA1 expression significantly affected DFS. In conclusion, HMGA1 and RACGAP1 may be potential prognostic biomarkers for predicting the recurrence of HCC after surgical resection.

show abstract

HMGA1 Overexpression is Associated With the Malignant Status and Progression of Breast Cancer

Cited by 13 publications

References 28 publications

Comparative Analysis of Putative Prognostic and Predictive Markers in Neuroblastomas: High Expression of PBX1 Is Associated With a Poor Response to Induction Therapy

Comparative Analysis of Putative Prognostic and Predictive Markers in Neuroblastomas: High Expression of PBX1 Is Associated With a Poor Response to Induction Therapy

High-Mobility Group AT-Hook 1 Served as a Prognosis Biomarker and Associated with Immune Infiltrate in Hepatocellular Carcinoma

Novel Gene Signatures as Prognostic Biomarkers for Predicting the Recurrence of Hepatocellular Carcinoma

Contact Info

Product

Resources

About